• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国马尔尼菲青霉的体外抗真菌药敏试验。

In vitro antifungal drug susceptibilities of Penicillium marneffei from China.

机构信息

Department of Dermatology and Venereology, First Affiliated Hospital, Guangxi Medical University, Nanning, China.

出版信息

J Infect Chemother. 2013 Aug;19(4):776-8. doi: 10.1007/s10156-012-0511-7. Epub 2012 Oct 28.

DOI:10.1007/s10156-012-0511-7
PMID:23104584
Abstract

Penicillium marneffei infections in immunocompromised patients are often fatal, but early treatment with appropriate antifungal agents may have a good prognosis. To select drugs for treating P. marneffei infection in Southern China, the susceptibilities of antifungal agents against P. marneffei isolates were evaluated. Twenty-five strains of P. marneffei were isolated from patients from 2008 to 2010 in Guangxi Province of China, and 14 strains were isolated from bamboo rats. The activity of voriconazole, fluconazole, itraconazole, terbinafine, and amphotericin B on the isolates was assessed by MIC analysis. Voriconazole MIC against strains of P. marneffei ranged from 0.004 to 0.25 mg/l, and it had the lowest MIC (geometric mean values, 0.04 mg/l) in comparison to the other antifungal agents. The MICs of other antifungal agents, in order of lowest to highest, were as follows: itraconazole, terbinafine, amphotericin B, and fluconazole. The results show voriconazole and itraconazole are active against P. marneffei isolates in vitro, and terbinafine may have unrealized usefulness in the treatment of infections caused by this yeast form.

摘要

免疫功能低下患者感染马尔尼菲青霉通常是致命的,但早期使用适当的抗真菌药物治疗可能有良好的预后。为了选择药物治疗中国南方的马尔尼菲青霉感染,评估了抗真菌药物对马尔尼菲青霉分离株的敏感性。从 2008 年至 2010 年,从广西的患者中分离出 25 株马尔尼菲青霉,其中 14 株从竹鼠中分离。通过 MIC 分析评估了伏立康唑、氟康唑、伊曲康唑、特比萘芬和两性霉素 B 对分离株的活性。伏立康唑对马尔尼菲青霉株的 MIC 范围为 0.004 至 0.25mg/L,与其他抗真菌药物相比,其 MIC(几何均数,0.04mg/L)最低。其他抗真菌药物的 MIC 按从低到高的顺序排列如下:伊曲康唑、特比萘芬、两性霉素 B 和氟康唑。结果表明,伏立康唑和伊曲康唑对体外马尔尼菲青霉分离株具有活性,特比萘芬在治疗这种酵母形式引起的感染方面可能具有未实现的用途。

相似文献

1
In vitro antifungal drug susceptibilities of Penicillium marneffei from China.中国马尔尼菲青霉的体外抗真菌药敏试验。
J Infect Chemother. 2013 Aug;19(4):776-8. doi: 10.1007/s10156-012-0511-7. Epub 2012 Oct 28.
2
In vitro comparison of terbinafine and itraconazole against Penicillium marneffei.特比萘芬和伊曲康唑对马尔尼菲青霉的体外比较。
Antimicrob Agents Chemother. 2000 May;44(5):1407-8. doi: 10.1128/AAC.44.5.1407-1408.2000.
3
In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis.体外抗真菌药物氟康唑、伊曲康唑、伏立康唑和特比萘芬治疗甲真菌病的活性。
Clin Exp Dermatol. 2010 Aug;35(6):658-63. doi: 10.1111/j.1365-2230.2009.03698.x. Epub 2009 Oct 23.
4
In vitro antifungal-drug susceptibilities of mycelial and yeast forms of Penicillium marneffei isolates in Cambodia.柬埔寨马尔尼菲青霉菌株丝状和酵母形式的体外抗真菌药物敏感性
J Clin Microbiol. 2006 Nov;44(11):4208-10. doi: 10.1128/JCM.00902-06. Epub 2006 Sep 13.
5
Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong, China.棘白菌素类、唑类和两性霉素 B 对中国广东 HIV 感染患者马尔尼菲篮状菌酵母相的敏感性分析。
Eur J Clin Microbiol Infect Dis. 2018 Jun;37(6):1099-1102. doi: 10.1007/s10096-018-3222-x. Epub 2018 Mar 13.
6
Caenorhabditis elegans: a simple nematode infection model for Penicillium marneffei.秀丽隐杆线虫:马尔尼菲青霉的一种简单线虫感染模型。
PLoS One. 2014 Sep 30;9(9):e108764. doi: 10.1371/journal.pone.0108764. eCollection 2014.
7
In vitro interactions of micafungin with amphotericin B, itraconazole or fluconazole against the pathogenic phase of Penicillium marneffei.米卡芬净与两性霉素B、伊曲康唑或氟康唑在体外对马尔尼菲青霉致病阶段的相互作用。
J Antimicrob Chemother. 2009 Feb;63(2):340-2. doi: 10.1093/jac/dkn494. Epub 2008 Dec 2.
8
Antifungal activity of antifungal drugs, as well as drug combinations against Exophiala dermatitidis.抗真菌药物的抗真菌活性,以及针对皮炎外瓶霉的药物联合治疗。
Mycopathologia. 2011 Feb;171(2):111-7. doi: 10.1007/s11046-010-9358-6. Epub 2010 Aug 29.
9
In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.泊沙康唑、氟康唑、伊曲康唑、伏立康唑和两性霉素B对大量临床重要霉菌和酵母菌的体外活性。
Antimicrob Agents Chemother. 2006 Jun;50(6):2009-15. doi: 10.1128/AAC.00163-06.
10
Activity of Posaconazole against Talaromyces marneffei by Broth Microdilution and Etest Methods and Comparison to Itraconazole, Voriconazole, and Anidulafungin.泊沙康唑通过肉汤微量稀释法和Etest法对马尔尼菲篮状菌的活性及其与伊曲康唑、伏立康唑和阿尼芬净的比较
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.01480-16. Print 2017 Mar.

引用本文的文献

1
Exploring the diversity and pathogenicity of species isolated from clinical in Southern China.探索中国南方临床分离菌株的多样性及致病性。
Front Microbiol. 2025 Jun 26;16:1610481. doi: 10.3389/fmicb.2025.1610481. eCollection 2025.
2
Voriconazole is inferior to amphotericin B deoxycholate as the initial induction therapy for HIV-associated Talaromyces marneffei fungemia: A multicenter retrospective study.伏立康唑作为HIV相关马尔尼菲篮状菌血症的初始诱导治疗不如脱氧胆酸两性霉素B:一项多中心回顾性研究。
PLoS Negl Trop Dis. 2025 Apr 8;19(4):e0013012. doi: 10.1371/journal.pntd.0013012. eCollection 2025 Apr.
3
Disseminated Combined and Bloodstream Infection Presenting as Gastrointestinal Perforation in a Patient with CARD9 Gene Mutation.
一例携带CARD9基因突变的患者出现播散性混合感染及血流感染并表现为胃肠道穿孔
Infect Drug Resist. 2024 Oct 31;17:4783-4790. doi: 10.2147/IDR.S479629. eCollection 2024.
4
New Polyene Macrolide Compounds from Mangrove-Derived Strain GXIMD 06359: Isolation, Antifungal Activity, and Mechanism against .新型多烯大环内酯化合物来自红树林来源菌株 GXIMD 06359: 分离、抗真菌活性及对. 的作用机制
Mar Drugs. 2024 Jan 8;22(1):38. doi: 10.3390/md22010038.
5
Development and validation of a colorimetric antifungal susceptibility testing method for the dimorphic fungus Talaromyces marneffei.显色法测定二相性真菌马尔尼菲篮状菌抗真菌药物敏感性的方法的建立和验证。
Med Mycol. 2023 Nov 6;61(11). doi: 10.1093/mmy/myad111.
6
Talaromyces marneffei infection with IFNGR1 gene mutation in a patient with negative Anti-Interferon-γ autoantibodies.马尔尼菲篮状菌感染伴 IFNGR1 基因突变的抗干扰素-γ自身抗体阴性患者。
An Bras Dermatol. 2024 Mar-Apr;99(2):233-237. doi: 10.1016/j.abd.2023.03.006. Epub 2023 Nov 3.
7
Comparison of in vitro Susceptibilities of in Mold and Yeast Forms in Malaysia.马来西亚霉菌和酵母形态体外药敏性比较。
Infect Drug Resist. 2023 Mar 22;16:1629-1635. doi: 10.2147/IDR.S398743. eCollection 2023.
8
Osteoarticular Mycoses.骨与关节真菌病。
Clin Microbiol Rev. 2022 Dec 21;35(4):e0008619. doi: 10.1128/cmr.00086-19. Epub 2022 Nov 30.
9
MALDI-TOF MS-Based Clustering and Antifungal Susceptibility Tests of Isolates from Fujian and Guangxi (China).基于基质辅助激光解吸电离飞行时间质谱的中国福建和广西分离株聚类及抗真菌药敏试验
Infect Drug Resist. 2022 Jul 1;15:3449-3457. doi: 10.2147/IDR.S364439. eCollection 2022.
10
Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei.马尔尼菲青霉菌所致播散性感染患者伊曲康唑的群体药代动力学和药效学。
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0063621. doi: 10.1128/AAC.00636-21. Epub 2021 Aug 9.